Consumer health group Haleon (LSE:HLN) reported third-quarter 2026 revenue of £2.87 billion, with organic growth of 2.6%. It now expects organic revenue growth of around 2.5% for 2026 and has started a share buyback of up to £500 million.

What was announced

Haleon plc published its trading statement for the three months to 30 September 2026 on 29 October, together with a separate notice confirming that a share buyback programme of up to £500 million had commenced.

Chief executive Brian McNamara said: "Our third quarter organic revenue growth of 2.6% was below our expectations as we navigated softness across some of our categories including weaker cough, cold and flu consumption." He added that the group had delivered solid performances in Oral Health and that its turnaround plan in North America "continues to make progress", and said the group is clear on where it needs to improve and is taking action to deliver better performance despite challenging markets.

The numbers

Group revenue for the quarter was £2,868 million, up 2.5% on a reported basis from £2,799 million. Organic growth of 2.6% comprised price gains of 2.1% and volume/mix growth of 0.5%. Currency movements had no net effect, and net M&A reduced growth by 0.1 percentage points. Over the nine months, organic revenue growth was also 2.6%, with reported growth of 2.3%. The statement gave no adjusted operating profit or margin figures for the quarter.

By region, North America delivered organic growth of 2.5% on revenue of £992 million, and Asia Pacific grew 3.9% to £593 million. The International region, which covers Latin America, the Middle East and Africa and the India subcontinent, rose 6.9% to £485 million. Europe declined 0.6% to £798 million, with the company citing difficult trading in Germany and Central and Eastern Europe, where market volumes fell by low single digits.

By category, Oral Health was again the standout, with organic growth of 8.8% on revenue of £930 million. Sensodyne grew by double digits, including double-digit growth in India and China, while parodontax and denture care also contributed. Digestive Health grew 2.5%, helped by double-digit growth at Benefiber, and Pain Relief edged up 0.5%. Respiratory Health fell 2.0% on weaker cough, cold and flu consumption and lower orders in North America and Europe. Vitamins, minerals and supplements slipped 0.5%, and Therapeutic Skin Health and Other declined 0.7%.

Guidance and headwinds

Haleon said it now expects organic revenue growth of around 2.5% for 2026. It continues to expect high-single-digit growth in adjusted operating profit at constant currency, net interest of about £255 million and an adjusted effective tax rate of about 24.5%. The statement did not state the previous organic growth guidance.

The guidance takes account of two specific factors. A raw material classification change has halted imports of Centrum's OTC-registered products into China until further notice. Haleon said this was not related to quality or safety, and that these products generated about £75 million of revenue in 2025. In addition, the group is accelerating a new go-to-market model in Brazil into the fourth quarter, which it expects to reduce net revenue by about £15 million to £20 million in that quarter. Separately, Advil Liquid has received FDA approval and is due to begin shipping towards the end of the fourth quarter.

The buyback

The buyback of up to £500 million is being run by Citigroup Global Markets under an irrevocable agreement. It will end no later than 19 February 2027 and uses authority granted at the April 2026 AGM, under which up to 805.1 million shares may be bought. About 80% of the shares repurchased will be cancelled, and the rest held in treasury, partly to meet employee share plan obligations in 2027 and 2028. Haleon gave no net debt figure in the statement, saying only that profit and cash generation were driving de-leveraging.